Accueil   Diary - News   All news GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

 

 

  • Based on R&D strategic reasons, Servier declines option to license and to further fund the development of GNbAC1 in MS

 

  • Servier will continue to support GeNeuro as a shareholder

 

  • Based on positive Phase IIb 12-month results, GeNeuro will pursue further development and worldwide partnering options


Paris, France and Geneva, Switzerland, September 18, 2018 – 07:30am CEST – Servier and GeNeuro (Euronext Paris: CH0308403085 – GNRO) announced today that GeNeuro has regained worldwide rights ex US and Japan to its lead compound GNbAC1 in multiple sclerosis (MS) from Servier. In 2014, Servier acquired an option to license the development and commercialization of GNbAC1 for MS in all territories ex-US and Japan for €37.5 million. Servier made the decision to decline this option based on R&D strategic reasons and international development priorities. Servier will continue supporting GeNeuro as a shareholder.

 

 

Read the full press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree